{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000195","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.196170+00:00","generated_at":"2026-06-08T21:13:39.722941+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026","bullets":["Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.","Cash, equivalents & marketable securities of $516.6M as of Sept 30, 2023; projected runway into 2026.","First NDA for azenosertib targeted in 2026 for a gynecologic malignancy; numerous trials ongoing.","Mark Lackner, Ph.D., to succeed co-founder Kevin Bunker, Ph.D., as Chief Scientific Officer at year-end.","ZN-d5 development in AL amyloidosis discontinued to focus resources on azenosertib franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000195","json":"https://secwatch.observer/filing/0001725160-23-000195.json","markdown":"https://secwatch.observer/filing/0001725160-23-000195.md","text":"https://secwatch.observer/filing/0001725160-23-000195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/0001725160-23-000195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/zntl-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:13:39.722941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2f85e6043eee86f3bb7a7e385dfda58b688dd19","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023 and commented on certain business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/0001725160-23-000195-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}